<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/92064AFF-7AF9-4899-B8E8-BF602C8F2623"><gtr:id>92064AFF-7AF9-4899-B8E8-BF602C8F2623</gtr:id><gtr:name>Lonza Biologics Plc</gtr:name><gtr:address><gtr:line1>228 BATH ROAD , SLOUGH</gtr:line1><gtr:city>BERKSHIRE</gtr:city><gtr:postCode>SL1 4DX</gtr:postCode><gtr:region>South East</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/92064AFF-7AF9-4899-B8E8-BF602C8F2623" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>92064AFF-7AF9-4899-B8E8-BF602C8F2623</gtr:id><gtr:name>Lonza Biologics Plc</gtr:name><gtr:address><gtr:line1>228 BATH ROAD , SLOUGH</gtr:line1><gtr:city>BERKSHIRE</gtr:city><gtr:postCode>SL1 4DX</gtr:postCode><gtr:region>South East</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>465314.0</gtr:offerGrant><gtr:projectCost>930627.0</gtr:projectCost></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C6D0044A-2CD2-4167-B90B-922AF53E361F" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>C6D0044A-2CD2-4167-B90B-922AF53E361F</gtr:id><gtr:name>University of Kent</gtr:name><gtr:address><gtr:line1>The Registry</gtr:line1><gtr:line4>Canterbury</gtr:line4><gtr:line5>Kent</gtr:line5><gtr:postCode>CT2 7NZ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>0.0</gtr:offerGrant><gtr:projectCost>0.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/94C2B09D-2AA0-45BB-B13E-8132B6735EAD"><gtr:id>94C2B09D-2AA0-45BB-B13E-8132B6735EAD</gtr:id><gtr:firstName>Andy</gtr:firstName><gtr:surname>Racher</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=102621"><gtr:id>397B1A06-5765-4A08-B8B5-142E68EF66E2</gtr:id><gtr:title>Translation of Step-changing Bioprocesses and Expression System Technologies for Next Generation Protein Biologics Production in CHO Cells</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Collaborative R&amp;D</gtr:grantCategory><gtr:grantReference>102621</gtr:grantReference><gtr:abstractText>Chinese hamster ovary (CHO) cells are the main production host for &amp;gt;US$145billion/yr of protein

biologics used as medicines for a range of diseases. The CHO platform is mature when considering

production of monoclonal antibodies, but new format non-native molecules such as fusion proteins,

antibody fragments and other exotic molecules remain difficult to express (DTE) in this, or any other

host. This project builds upon proof of concept work demonstrating that engineering the CHO chassis,

together with growth media manipulation, increases both the yield and quality of a number of DTE

proteins that are in development for application to unmet clinical needs and diseases with no current

treatments. The project will advance the technology readiness level of our preliminary findings beyond

proof-of-concept to deliver the commercialization of new CHO cell systems for DTE proteins and

associated bioprocesses ready for industrial application to produce these important new medicines.</gtr:abstractText><gtr:fund><gtr:end>2019-08-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2016-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>465314</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">102621</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>